The purpose of this study is to see if a second course of treatment with ianalumab can help people who previously received this medication and experienced improvement but then had their condition return. For people with immune thrombocytopenia, the study will look at whether the second treatment can maintain platelet counts and reduce the need for additional treatments. For people with warm-antibody autoimmune hemolytic anemia, the study will check if the second treatment can maintain hemoglobin levels, which reflects the amount of red blood cells in the blood, and reduce symptoms of anemia.

Participants in this study must have previously taken part in earlier research studies with ianalumab and must have experienced benefit from the treatment but later had their condition worsen. The study will involve receiving ianalumab infusions and regular monitoring visits where blood samples will be taken to measure blood cell counts and check for any side effects. The treatment period will last up to 16 weeks, and participants will be followed for several months afterward to assess how long the benefits last and to monitor safety. During the study, some participants may receive additional supportive treatments or rescue medications if needed to manage their symptoms.

The purpose of the study is to evaluate the safety and tolerability of Povetacicept in individuals with these autoimmune conditions. Participants in the study will receive Povetacicept and will be monitored to assess how their bodies respond to the treatment. The study will look at various factors, including any side effects that may occur and how the medication affects the participants’ health over time.

Throughout the study, participants will receive regular check-ups and assessments to ensure their well-being and to gather information on the effectiveness of the treatment. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. This trial aims to provide valuable insights into the potential benefits and risks of using Povetacicept for treating autoimmune cytopenias.

The main purpose of the study is to determine if ianalumab can help maintain healthy blood levels in people with wAIHA. During the study, participants will be randomly assigned to receive either ianalumab or placebo. The study will measure whether the treatment can increase and maintain hemoglobin levels, which is an important component of red blood cells that carries oxygen throughout the body.

The treatment period lasts for 32 weeks, during which participants will receive regular infusions. Throughout the study, doctors will monitor blood levels, check for side effects, and track how participants feel. Some participants may also receive standard supportive care medications such as corticosteroids, antihistamines, or other treatments commonly used for this condition.

The purpose of the study is to evaluate the safety and effectiveness of Obexelimab in treating patients with wAIHA. The study is divided into three parts. In the first part, the safety and appropriate dose of Obexelimab will be confirmed. In the second part, the treatment will be compared to the placebo to see if it helps improve anemia. In the third part, patients will continue to receive Obexelimab to further assess its safety and benefits over a longer period.

Participants will receive weekly injections and will be monitored regularly to check their response to the treatment. The study aims to see if Obexelimab can help increase hemoglobin levels, which are important for carrying oxygen in the blood, and reduce the need for additional treatments like blood transfusions. The trial will also look at how well patients tolerate the treatment and any side effects they may experience.